Engineered immune cells take aim at Hard-to-Treat pancreatic cancer
NCT ID NCT04146298
First seen Jan 04, 2026 · Last updated Apr 26, 2026 · Updated 19 times
Summary
This study tests a personalized cell therapy for people with advanced pancreatic cancer that has a specific genetic change (KRAS G12V). The treatment uses the patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The goal is to see if this approach is safe and can shrink tumors. About 30 participants with this specific mutation and tissue type (HLA-A*11:01) will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Changhai Hospital
RECRUITINGShanghai, 200433, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.